India’s pharmaceutical industry is again confronting a question central to public trust: how can medicines be promoted without compromising the independence of clinical decisions?
The Department of Pharmaceuticals has constituted a three-member committee to review pharmaceutical marketing practices and examine the effectiveness of existing monitoring and enforcement mechanisms. Its review includes the Uniform Code for Pharmaceutical Marketing Practices, 2024, and is expected to consider gaps in oversight, transparency and accountability.
The important distinction is that a review has been initiated; new restrictions or penalties have not yet been announced. Any change would depend on the committee’s recommendations and subsequent government decisions. expresspharma.in
For the industry, the issue goes beyond reputational risk. Pharmaceutical companies have a legitimate need to provide doctors with accurate scientific information about medicines. At the same time, prescribing decisions must remain grounded in patient need and clinical evidence—not inducements.
The Pharma Times believes the committee should consider whether complaints are easy to submit, how consistently they are investigated, and whether outcomes are sufficiently transparent. Smaller manufacturers should receive clear, practical guidance on compliant medical education, promotional material and interactions with healthcare professionals.
Industry leaders should not wait for a new rulebook. Internal approval systems, training for sales teams and independent compliance reviews can demonstrate that ethical marketing is a business responsibility, not merely a regulatory requirement.
The public interest lies in a simple principle: confidence in a medicine begins with confidence in the information surrounding it.
